Oppenheimer raised the firm’s price target on MoonLake Immunotherapeutics (MLTX) to $35 from $30 and keeps an Outperform rating on the shares. MoonLake hosted a virtual Investor Day highlighting new Phase 2 data of sonelokimab in axial spondyloarthritis, discussing outcomes from the recent Type B meeting with the FDA on hidradenitis suppurativa, and the 2026 catalyst-rich setup. With SLK potential approval in HS in Q3 on track, Oppenheimer is a buyer into several value-generating clinical catalysts this year that can put SLK back on the I&I map as a potentially strategic blockbuster asset.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MLTX:
- Sonelokimab: Strong HS and AxSpA Data, Clear Regulatory Path Support Best‑in‑Class Potential and Buy Rating
- MoonLake Highlights Positive S-OLARIS Data and Investor Day
- MoonLake announces results from Phase 2 trial of Sonelokimab
- MoonLake Immunotherapeutics: Fast-Track Sonelokimab and Multi-Indication Late-Stage Catalysts Underpin Buy Rating and $32 Target
- MoonLake announces FDA granted Fast Track designation for sonelokimab